Introduction
As per the India HIV Estimation 2019 report, in India, there were an estimated 23.48 lakh (17.98 lakh–30.98 lakh) people living with HIV (PLHIV) in 2019. Maharashtra was estimated to have the highest number of PLHIV (3.96 lakh).[1] The AIDS dementia complex is one of the most common and clinically important complications of HIV infection. HIV-associated dementia (HAD) is more prevalent in PLHIV who have severe immunosuppression, high viral loads in the cerebrospinal fluid, and advanced HIV as indicated by anemia and hypoalbuminemia.[2] PLHIV having HAD are seen to have poorer abilities when it comes to self-care including drug regimen adherence, compared to those without HAD with a lesser median survival time.[3]

Early identification of HAD and the treatment of underlying HIV is associated with better neurocognitive outcomes and higher survival rates for PLHIV.[4] Overt dementia is often picked up by the treating physician but underlying subclinical dementia may be missed. The use of screening tools provides a good alternative to a psychiatrist’s diagnosis in resource-limited settings like the site of this study.

Materials and Methods:
The assessment of dementia was done using the International HIV Dementia Scale. Statistical Analysis Used: Backward binomial logistic regression. Results: Both duration of treatment and duration since diagnosis of HIV were found to be significantly associated with the presence of AIDS dementia. Patients having stage 4 disease and CD4 counts <200 were likelier to have dementia as compared to other participants. People with an unknown mode of transmission had higher odds of having AIDS dementia than persons having a mode of transmission as via blood/blood products/invasive procedures/mother-to-child transmission/IV drug abuse. Binomial logistic regression revealed mode of transmission or rather its awareness to be the strongest contributor.

Conclusions: These findings highlight the need for early screening and diagnosis of HIV-associated dementia in patients living with HIV and that of early assessment and initiation of treatment.

Key words: Dementia, HIV/AIDS, International HIV Dementia Scale, Mumbai
**Materials and Methods**

**Duration and participants**
A cross-sectional study was conducted over a duration of 18 months at the antiretroviral outpatient department of our institute.

The inclusion criteria involved all HIV-positive patients above 12 years of age, with HIV-1 or HIV-2 positive status. The exclusion criteria included history or examination suggestive of cerebrovascular accident, central nervous system infections like meningitis and encephalitis, Parkinson’s disease, or history of previously diagnosed primary psychiatric disorder.

An approval was taken from the institutional ethics committee and National AIDS Control Organization. One hundred and eighty participants were enrolled in the study. Written informed consent or assent was obtained. Consecutively, HIV-positive patients were enrolled in the study irrespective of whether on ART or not.

**Procedure and assessment of dementia**
The assessment of dementia was initially undertaken using 2 scales: the Mini Mental Status examination scale (MMSE) and the IHDS. The validity of MMSE in subcortical disease has been criticized and thus its application as a screening tool is discouraged.[7] Hence, the MMSE scoring was not used for further analysis and its findings will not be mentioned henceforth.

**International HIV Dementia Scale**
IHDS is an interviewer-administered performance measure that assesses 3 domains: motor speed (timed finger tapping), psychomotor speed (timed alternating sequence test), and memory recall (recall of 4 items). Patients with a total score ≤10 should be evaluated further for possible dementia with the gold standard being a psychiatric evaluation.[8]

Patients who had an IHDS score of <10 were included in the group: patients with possible AIDS dementia and rest of the patients categorized as patients without AIDS dementia.

**Data analysis**
Data were analyzed after dividing patients into two groups, i.e., patients with possible AIDS dementia and patients without possible AIDS dementia (based on their IHDS scoring). The variables considered were their age, gender, time since diagnosis, duration of therapy, CD4 count, use of zidovudine, mode of transmission, and presence or absence of tuberculosis as a comorbidity. Continuous data were categorized, and univariate analysis was done for the aforementioned factors using the Chi-square test. Odds ratios were calculated for individual categories. Variables found to be statistically significant with $P < 0.05$ were considered for backward stepwise binomial logistic regression. All analysis was conducted using SPSS version 28 [IBM Corp (International Business Machines Corporation). Released 2021. IBM SPSS Statistics for Windows, Version 28.0. Armonk, NY (New York): IBM Corp - United States of America].

**Results**
Out of a total of 180 participants, 143 were found to be patients without AIDS dementia [Table 1]. 37 patients had AIDS dementia according to the criterion (20.55%).

The mean age of all participants was 43.17 years. Among patients with and without AIDS dementia, the mean age was 43 and 44 years, respectively.

Age ($\chi^2 = 0.205, P = 0.903$) and sex ($\chi^2 = 0.287, P = 0.592$) were not significantly associated with AIDS dementia at a significance level of 0.05.

Both duration of treatment ($\chi^2 = 16.789, P = 0.002$) and duration since diagnosis ($\chi^2 = 16.072, P = 0.001$) of HIV were found to be significantly associated with the presence of AIDS dementia at a significance level of 0.05. Patients diagnosed within the past year had statistically significant odds of having AIDS dementia (OR = 11.29 [95% CI = 2.30–55.47]) as compared to patients started on treatment 3–6 years ago. The same was found to be true for patients not receiving treatment at all (OR = 9.81 [95% CI = 1.53–40]). However, the patient’s current treatment status ($\chi^2 = 2.726, P = 0.099$) was not found to be significantly associated with AIDS dementia.

Zidovudine use did not have a statistically significant association with the presence of AIDS dementia ($\chi^2 = 3.259, P = 0.72$).

The WHO clinical stage was found to be significantly associated with possible AIDS dementia ($\chi^2 = 34.109, P < 0.001$). Patients having stage 4 disease were more likely to have AIDS dementia than patients with stage 1 disease (OR = 13.75 [95% CI = 4.85–39.01]). The presence of tuberculosis as a comorbidity was also found to be significantly associated with AIDS dementia ($\chi^2 = 13.762, P < 0.001$; OR = 4.14 [95% CI = 1.89–9.05]).

The possible mode of transmission of HIV was categorized as sexual, others (including blood/blood products/invasive procedures/mother to child transmission/IV drug abuse), and not known with certainty. It was found to have a statistically significant association with the presence of possible AIDS dementia ($\chi^2 = 6.026, P < 0.049$). People with an unknown mode of transmission were found to have statistically significant higher odds of having AIDS dementia than persons having a mode of transmission as mentioned under ‘others’ (OR = 8.64 [95% CI = 1.03–72.55]).

CD4 count was found to be statistically significant in its association with possible AIDS dementia ($\chi^2 = 22.100, P < 0.001$). Patients with CD4 counts of <200 were found to have significantly increased odds of having AIDS dementia as compared to patients with CD4 counts of more than 400 (OR = 15.26 [95% CI = 3.44–67.78]).

Binomial logistic regression was performed with the variables: duration since diagnosis, duration since treatment, CD4 counts, presence or absence of TB, clinical stage, and mode of transmission [Table 2]. The Step 1 model was selected as being most accurate (2 log likelihood ratio = 91.338; Nagelkerke R square = 0.569), which included the variables: duration since diagnosis, duration since treatment, CD4 counts, presence or absence of TB, clinical stage, and mode of transmission. It showed an 87.8% overall accuracy and 66.7% accuracy in predicting possible AIDS dementia [Table 3]. Mode of transmission was found to have the strongest association (largest difference in model with term removed) followed by duration of treatment and clinical stage [Table 4].
Joshi, et al.: Analysis of HIV-associated dementia in a tertiary care hospital

| Variable                              | Possible AIDS dementia | \( \chi^2 \) | \( P \) | OR (95% CI) |
|----------------------------------------|------------------------|-------------|--------|-------------|
| Duration since diagnosis (years)       |                        |             |        |             |
| Up to 1                                | Yes 20                 | 16.072      | 0.001  | 4.83 (1.47-15.87) |
| 1-3                                    | No 30                  |             |        |             |
| 3-6                                    | Yes 4                  | 1.21 (0.27-5.35) |
| >6                                     | No 29                  |             |        | 1           |
| Duration of treatment (years)          |                        |             |        |             |
| No treatment                           | Yes 9                 | 16.789      | 0.002  | 9.81 (1.53-40) |
| Up to 1                                | No 19                 |             |        |             |
| 1-3                                    | Yes 4                 | 11.29 (2.30-55.47) |
| 3-6                                    | No 30                 |             |        | 2.20 (0.38-12.89) |
| >6                                     | Yes 6                 |             |        | 1           |
| WHO clinical stage                     |                        |             |        |             |
| 1                                      | Yes 5                 | 34.109      | <0.001 | 1.21 (0.27-5.35) |
| 2                                      | No 82                 |             |        |             |
| 3                                      | Yes 6                 | 13.762      | <0.001 | 1.09 (0.31-3.83) |
| 4                                      | No 29                 |             |        | 3.53 (0.71-17.49) |
| Presence of TB as comorbidity          |                        |             |        |             |
| Present                                | Yes 26                | 13.762      | <0.001 | 1           |
| Absent                                 | No 52                 |             |        |             |
| Mode of transmission                   |                        |             |        |             |
| Sexual                                 | Yes 24                | 6.026       | 0.049  | 4.32 (0.55-33.97) |
| Others                                 | No 100                |             |        |             |
| Unknown                                | Yes 12                | 8.64 (1.03-72.55) |
| CD4 counts (n=165)                     |                        |             |        |             |
| 0-200                                  | Yes 26                | 22.100      | <0.001 | 15.26 (3.44-67.78) |
| 201-400                                | No 46                 |             |        | 4.22 (0.77-23.02) |
| >400                                   | Yes 32                |             |        | 1           |

CI=Confidence interval; WHO=World Health Organization; OR=Odds ratio; NA=Not available; TB=Tuberculosis

Discussion

With the widespread use of HAART in developing countries in the mid-1990s, there was a dramatic fall off in the rates of AIDS dementia,[9] with cases usually associated with specific risk factors including female sex, being elderly, higher HIV viral titers, low CD4+ counts,[10] non-use of HAART, lower socioeconomic group, substance abuse, and iron-deficiency anemia.[11,12] Along these lines, this was the first study of its kind examining possible HIV dementia purely through a screening tool (IHDS) in an urban tertiary care setup in Mumbai. The prevalence of possible AIDS dementia in our study was found to be 20.55%, which was lower than the prevalence found in other Indian studies like the one conducted by Saini et al.,[13] which described a prevalence of 32.50% for HAND.[9] This difference could be explained possibly by differences in individual population characteristics and alterations based on the sample size. Age and sex were not found to be significantly associated with AIDS dementia, which also corroborates other studies such as one by Sevigny et al.,[14] Nakku et al.,[15] and Habib et al.[16]

Patients with a longer duration since diagnosis and longer durations of treatment were both found to have statistically significant associations with the presence of AIDS dementia. One explanation for this might be poorer control of disease in recently diagnosed subjects due to poorer health-seeking behavior as compared to their counterparts in this group, resulting in their possible exclusion from routine screening measures in tertiary care setups. The possibility of patients harboring the infection for much longer periods of time than they are aware of should be taken into consideration when interpreting data related to duration of HIV illness. Although untreated disease is a well-known risk factor for AIDS dementia and it is suggested that early initiation of treatment may also result in superior or preserved neurocognitive performance,[17] our study did not find such an association possibly due to a smaller number of subjects having possible AIDS dementia.

Our study examined the use of zidovudine among patients and its association with AIDS dementia and we found no statistically significant association between the same. The effect of CNS penetration of ART drugs as described by their CNS penetration effectiveness rank (CPE), its subsequent impact on AIDS dementia, and the role of CPE in the management of AIDS dementia remains a controversy despite considerable research.[18-20] Zidovudine has a CPE rank of 4 (tenofovir = 1, emtricitabine = 3, lamivudine = 2) and hence was selected to study any possible association of CPE rank on AIDS dementia.

Clinical staging also had a significant association with the development of AIDS dementia, concurrent with the
findings of other studies, HIV encephalopathy is considered an AIDS defining illness; however, similar considerations have not been made for AIDS dementia. We found an increased prevalence in patients with clinical stage 4. However, 29.72% of cases belonged to a lower clinical stage (1-3), which emphasizes the need to incorporate routine screening for AIDS dementia even in the absence of symptoms suggestive of cognitive dysfunction or Stage 4 HIV illness. In lower resource settings where psychiatrist interview is not available routinely, IHDS has been shown to be a reliable tool and can be utilized as part of the routine patient interview.

The relationship between CD4 count and AIDS Dementia is well established, and our study also bears witness to this association with the highest prevalence being found in subjects with CD4 counts <100. This also emphasizes the need for thorough CD4 count regulation to prevent the development of AIDS dementia and further morbidity due to it.

The presence of tuberculosis as a comorbidity was found to be statistically significant in its association with AIDS dementia. This may be attributed to tuberculosis itself being more prevalent among patients with lower CD4 counts and hence advanced disease. A poorer control of disease represented by the presence of tuberculosis may further indicate a more pressing need to assess for AIDS dementia in these subjects.

Patients with an unknown mode of transmission were also found to have a higher incidence of AIDS dementia as compared to those with known modes of transmissions. The patients belonging to the latter groups may undergo more frequent screening and diagnostic testing for HIV as compared to their counterparts with unknown modes of transmission, due to them being construed as “high risk” for the disease, which may result in earlier detection in these patients and subsequent establishment of treatment. This may be further interpreted as a need for more widespread education regarding HIV and its transmission to ensure timely testing.

Mode of transmission was found to be the strongest predictor based on binomial logistic regression. This finding however may be interpreted in the context of disease duration, health-seeking behavior, and knowledge of the illness all affecting a person’s awareness of their mode of transmission and hence resulting in the particularly observed strength of association in this population.

Limitations
During the time duration of this study, viral load was being done only for selected patient groups at our center. Hence, the correlation of viral load with AIDS dementia cannot be analyzed in this study. Socioeconomic data were not analyzed in this study. In scales such as MMSE, the educational status of the patient plays a role in interpreting the outcome. Although the IHDS does not have such a caveat in its interpretation, socioeconomic factors may affect outcomes related to AIDS dementia and were not analyzed in this study.

Table 3: Variables in the binomial logistic regression model (step 1 of backward stepwise regression) (n=164)

| Step 1* | Step 1* | Step 1* | Step 1* | Step 1* | Step 1* |
|---------|---------|---------|---------|---------|---------|
| Variable (s) entered on step 1: Duration since diagnosis, duration of treatment, clinical stage, TB status, mode of transmission, CD4 count. | Duration since diagnosis | Duration of treatment | WHO clinical stage | TB present | Mode of transmission |
| n=164 | n=164 | n=164 | n=164 | n=164 | n=164 |
| Wald | SE | P | Wald | SE | P | Wald | SE | P | Wald | SE | P | Wald | SE | P |
| CD4 count | Mode of transmission (years) | WHO clinical stage | TB present | Mode of transmission | CD4 count |
| Duration since diagnosis (years) | -0.009 | 1.697 | 0.000 | 1 | 0.996 | 0.991 | 0.036 | 27.560 | 1 | 0.000 | 1 | 7.370 | 3-6 | 19.954 | 7992.108 | 0.000 | 1 | 0.000 | 0.000 |
| Duration of treatment (years) | -1.687 | 1.259 | 1.795 | 1 | 0.180 | 0.185 | 0.016 | 2.184 | 1 | 0.004 | 0.919 | 0.228 | 17.344 | 7992.108 | 0.000 | 1 | 0.996 | 0.572 |
| WHO clinical stage | -3.346 | 1.102 | 9.224 | 1 | 0.002 | 0.035 | 0.004 | 0.305 | 2 | 0.000 | 0.590 | 0.058 | 0.000 | 2 | 1 | 0.000 | 2 | 1 | 0.000 |
| Stage 1 | -0.482 | 0.678 | 0.504 | 1 | 0.478 | 0.618 | 0.163 | 2.335 | 1 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| Stage 2 | -0.845 | 0.921 | 0.841 | 1 | 0.359 | 0.430 | 0.071 | 2.612 | 1 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| TB present | -1.419 | 0.751 | 3.566 | 1 | 0.000 | 0.242 | 0.056 | 1.055 | 1 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| Mode of transmission | -22.704 | 8644.143 | 0.000 | 1 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| CD4 count | 6.834 | 2 | 0.033 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| 0-200 | -0.331 | 0.694 | 0.228 | 1 | 0.633 | 0.718 | 0.184 | 2.800 | 1 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| 201-400 | -2.481 | 0.949 | 6.834 | 1 | 0.000 | 0.084 | 0.013 | 0.537 | 1 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| Constant | 4.453 | 1.754 | 6.442 | 1 | 0.011 | 85.861 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |

*Based on conditional parameter estimates. Df=Degrees of freedom; WHO=World Health Organization; TB=Tuberculosis; CD4 count =CD4 count; SE=Standard error; Wald=Wald test; Df=Degrees of freedom; Sig=Significance probability; Exp(B)=Exponentiation of the B coefficient; CI=Confidence interval; Mode of transmission =Mode of transmission; Others (blood/blood products/MTCT/IV drug abuse/invasive procedures) =Others (blood/blood products/MTCT/IV drug abuse/invasive procedures); Duration since diagnosis =Duration since diagnosis; Duration of treatment =Duration of treatment; Clinical stage =Clinical stage; TB status =TB status; Mode of transmission =Mode of transmission; CD4 count =CD4 count; Mode of transmission =Mode of transmission.

Table 4: Impact of removal of individual variables on the model (n=164)

| Variable | Step 1 | Step 1 | Step 1 | Step 1 |
|----------|--------|--------|--------|--------|
| Step 1 | Model log likelihood | Change in Z log likelihood | df | Significance of the change |
| Duration since diagnosis | -48.690 | 6.043 | 3 | 0.110 |
| Duration of treatment | -53.008 | 14.678 | 4 | 0.005 |
| WHO clinical stage | -51.602 | 11.867 | 2 | 0.003 |
| TB status | -46.096 | 0.855 | 1 | 0.355 |
| Mode of transmission | -57.936 | 24.534 | 2 | <0.001 |
| CD4 count | -50.836 | 10.334 | 2 | 0.006 |

*Based on conditional parameter estimates. Df=Degrees of freedom; WHO=World Health Organization; TB=Tuberculosis.
Conclusions
The prevalence of possible AIDS dementia complex in our study was 20.55%. The incidence of AIDS dementia declined as the duration from diagnosis of HIV increased. Longer duration of treatment has benefitted HIV-positive patients with respect to the development of AIDS dementia. Patients in the late stages of HIV infection, low CD4 counts, an unknown mode of transmission, and tuberculosis were more likely to develop AIDS dementia. The IHDS is a good screening tool for AIDS dementia in HIV clinics, especially in low-resource settings.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1. The Press Information Bureau (PIB) 2020, Ministry of Health and Family Welfare. Available from: https://pib.gov.in/PressReleaseIframePage.aspx?PRID=1657072. [Last accessed on 2021 Nov 25].
2. Gannon P, Khan MZ, Kolson DL. Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol 2011;24:275.
3. Bouwman FH, Skolasky RL, Hes D, Selnos OA, Glass JD, Nance-Sproson TE, et al. Variable progression of HIV-associated dementia. Neurology 1998;50:1814-20.
4. Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 2011;19:137-42.
5. Bouwman FH, Skolasky RL, Hes D, Selnos OA, Glass JD, Nance-Sproson TE, et al. Variable progression of HIV-associated dementia. Neurology 1998;50:1814-20.
6. Marin-Webb V, Jessen H, Kopp U, Jessen AB, Hahn K. Validation of the international HIV dementia scale as a screening tool for HIV-associated neurocognitive disorders in a German-speaking HIV outpatient clinic. PLoS One 2016;11:e0168225.
7. Kami-Onaga K, Tateyama M, Kinjo T, Parrott G, Tominaga D, Takahashi-Nakazato A, et al. Comparison of two screening tests for HIV – Associated neurocognitive disorder suspected Japanese patients with respect to cART usage. PLoS One 2018;13:e0199106.
8. Sacktor NC, Wong M, Nakasujja N, Skolasky RL, Selnos OA, Musisi S, et al. The international HIV dementia scale: A new rapid screening test for HIV dementia. AIDS 2005;19:1367-74.
9. Bhaskaran K, Mussini C, Antinori A, Walker AS, Dorrucchi M, Sabin C, et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 2008;63:213-21.
10. Ellis RJ, Badree J, Vaida F, Letendre S, Heaton RK, Clifford D, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 2011;25:1747-51.
11. McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology. 1993;43:2245-52. doi: 10.1212/wnl.43.11.2245. PMID: 8232937.
12. Kallianpur AR, Wang Q, Jia P, Hulgan T, Zhao Z, Letendre SL, et al. Anemia and red blood cell indices predict HIV – Associated neurocognitive impairment in the highly active antiretroviral therapy era. J Infect Dis 2016;213:1065-73.
13. Saini S, Barar KV. Assessment of neurocognitive functions in HIV/AIDS patients on HAART using the international HIV dementia scale. Int J Nutr Pharmacol Neurol Dis 2014;4:252.
14. Sevigny JJ, Albert SM, McDermott MP, McArthur JC, Sacktor N, Conant K, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004;63:2084-90.
15. Nakku J, Kinyanda E, Hoskins S. Prevalence and factors associated with probable HIV dementia in an African population: A cross-sectional study of an HIV/AIDS clinic population. BMC Psychiatry 2013;13:126.
16. Habib AG, Yakasai AM, Owolabi LF, Ibrahim A, Habib ZG, Gadaji M, et al. Neurocognitive impairment in HIV-1-infected adults in Sub-Saharan Africa: A systematic review and meta-analysis. Int J Infect Dis 2013;17:e820-31.
17. Wright EJ. Neurological disease: The effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation. Curr Opin HIV AIDS 2009;4:447-52.
18. Koennecke HC, Belz W, Berfelde D, Endres M, Fitzek S, Hamilton F, et al. Factors influencing in-hospital mortality and morbidity in patients treated on a stroke unit. Neurology 2011;77:965-72.
19. Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, et al. Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology 2011;76:693-700.
20. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009;23:1359-66.
21. Kannmogne GD, Kuate CT, Cysique LA, Fonsah JY, Eta S, Doh R, et al. HIV-associated neurocognitive disorders in sub-Saharan Africa: A pilot study in Cameroon. BMC Neurol 2010;10:60.
22. Heaton RK, Grant I, Butters N, White DA, Kirson D, Atkinson JH, et al. The HNRC 500—neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 1995;1:231-51.
23. World Health Organization. WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV – Related Disease in Adults and Children. Switzerland: World Health Organization; 2007.